Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Adenocarcinoma 1

Interventions

pembrolizumab 213Cyclophosphamide 123Nivolumab 110Carboplatin 94fludarabine 81Gemcitabine 78Specimen Handling 74Bevacizumab 73Injections 71venetoclax 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 54Ipilimumab 50Temozolomide 46Lenalidomide 43Azacitidine 43Docetaxel 42Pemetrexed 41Rituximab 40Radiotherapy 40Oxaliplatin 40Fluorouracil 39Cetuximab 38durvalumab 37Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × 1-methyltryptophan × 1 year × Clear all
NCT02073123 2026-05-29

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Lumos Pharma

Phase 1/2 Completed
131 enrolled 23 charts
Dermatologic

Melanoma

NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Lumos Pharma

Phase 1/2 Completed
157 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡